Document is current
Any future updates will be listed below
-
Authors
Gardner, Wilf https://orcid.org/0000-0001-6211-9873
Sarrazin, David H. https://orcid.org/0000-0003-1326-3232
Balzinger, Martin
Marchese, Carole
Ragno, Axelle
Ramanathan, Chockalingam https://orcid.org/0000-0003-3668-4478
Veleanu, Maxime https://orcid.org/0000-0001-6760-3488
Vestring, Stefan https://orcid.org/0000-0001-9150-8712
Normann, Claus https://orcid.org/0000-0001-5693-8936
Bourgin, Patrice
Serchov, Tsvetan https://orcid.org/0000-0002-2234-2875
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SE 2666/2-1, SE 2666/2-3)
Fondation pour la Recherche Médicale (AJE201912009450)
Université de Strasbourg (USIAS 2020-035)
- License Information
-
More Information
Article History
Received: 16 January 2025
Revised: 26 August 2025
Accepted: 16 September 2025
First Online: 29 September 2025
Competing interests
: CN received lecture fees and advisory board honoraria from Novartis, Johnson & Johnson, Boehringer und Precisis. All other authors declare that they have no competing interests to disclose.
: The Chronobiotron animal facility (Strasbourg) is registered for animal experimentation (Agreement A67-2018-38). All procedures were performed in accordance with the German animal protection law (TierSchG), FELASA (), the guide for care and use of laboratory animals of the national animal welfare body GV-SOLAS ) and the EU Directive 2010/63/EU for animal experiments and were approved by the local animal welfare committee of the University of Freiburg (X-20/06R, 35-9185.81/G-19/44 and G-15/117) and University of Strasbourg (CREMEAS, APAFIS n°2020042818477700).
